DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Clinical trials for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new DLBCL - DIFFUSE LARGE B CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail aims to replace chemo for lymphoma patients
Disease control Not yet recruitingThis study tests a combination of three drugs (glofitamab, polatuzumab vedotin, and zuberitamab) as a chemotherapy-free treatment for people newly diagnosed with diffuse large B-cell lymphoma. The goal is to see if this approach can shrink or eliminate the cancer without the hars…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Li Zhiming • Aim: Disease control
Last updated May 26, 2026 04:35 UTC
-
Promising new combo targets hard-to-treat lymphoma in seniors
Disease control Not yet recruitingThis study tests a new combination of drugs for people aged 65 and older with a fast-growing type of lymphoma called double/triple-hit diffuse large B-cell lymphoma. Participants will receive six cycles of the CL-Pola-R-CHP regimen, which adds two newer drugs to a standard chemot…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated May 26, 2026 04:34 UTC
-
New combo therapy aims to beat tough lymphoma
Disease control Not yet recruitingThis study tests whether combining two powerful treatments—glofitamab and CAR-T cell therapy—can help people with a high-risk form of large B-cell lymphoma that has come back or not responded to prior treatment. About 24 participants will receive the combination and be monitored …
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated May 26, 2026 04:34 UTC
-
New hope for tough lymphoma: glofitamab under Real-World microscope
Disease control Not yet recruitingThis study looks at how well the drug glofitamab works for people with a type of blood cancer called diffuse large B-cell lymphoma that did not respond to or came back quickly after initial treatment. About 20 adults will be treated as part of their normal care, and researchers w…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New hope for lymphoma patients: two drug regimens face off in clinical trial
Disease control Not yet recruitingThis study tests two different chemotherapy combinations in 70 adults whose diffuse large B-cell lymphoma has returned more than a year after initial treatment. Participants will receive either the modified R-MINE regimen or the R-GemOx regimen for four 3-week cycles. The goal is…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: NA • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New hope for aggressive lymphoma: targeted combo aims for higher remission
Disease control Not yet recruitingThis study tests a new treatment for people with a fast-growing type of lymphoma called double-expressor DLBCL. It compares a standard chemo-immunotherapy regimen (CR-CHOP) to a newer combination (C Pola R-CHP+X) chosen based on each patient's genetic profile. The goal is to see …
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New hope for hard-to-treat lymphoma: experimental drug combo enters phase 3 trial
Disease control Not yet recruitingThis phase 3 trial compares a new drug (SCTB35) plus chemotherapy against a standard drug (rituximab) plus chemotherapy in about 101 adults with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if the new combination works b…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
15-Year Check-In: how long do modified immune cells last?
Knowledge-focused Not yet recruitingThis study follows 18 people who already received GF-CART01, a CAR T-cell therapy for certain blood cancers like lymphoma. Researchers will monitor participants for up to 15 years to see how long the modified cells stay in the body and whether any serious side effects appear. No …
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. • Aim: Knowledge-focused
Last updated May 20, 2026 11:57 UTC